Importantly, BTKi therapy overcomes the negative prognostic impact of U-CLL, based on longer follow-up of M-CLL and U-CLL patients treated with ibrutinib (34). This evidence concerns the gene IBTK and B-cell chronic lymphocytic leukemia.